Does OFATUMUMAB Cause Hyperleukocytosis? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Hyperleukocytosis have been filed in association with OFATUMUMAB (ARZERRA). This represents 0.0% of all adverse event reports for OFATUMUMAB.
7
Reports of Hyperleukocytosis with OFATUMUMAB
0.0%
of all OFATUMUMAB reports
6
Deaths
0
Hospitalizations
How Dangerous Is Hyperleukocytosis From OFATUMUMAB?
Of the 7 reports, 6 (85.7%) resulted in death.
Is Hyperleukocytosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OFATUMUMAB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does OFATUMUMAB Cause?
Fatigue (5,202)
Headache (4,430)
Pain (3,382)
Chills (3,372)
Pyrexia (3,370)
Influenza like illness (2,727)
Nausea (1,688)
Multiple sclerosis relapse (1,525)
Covid-19 (1,435)
Asthenia (1,393)
What Other Drugs Cause Hyperleukocytosis?
CYCLOPHOSPHAMIDE (55)
PREDNISONE (54)
TRETINOIN (52)
ARSENIC TRIOXIDE (49)
RITUXIMAB (49)
ACETAMINOPHEN (44)
VINCRISTINE (44)
DEXAMETHASONE (42)
PANTOPRAZOLE (38)
AMOXICILLIN (36)
Which OFATUMUMAB Alternatives Have Lower Hyperleukocytosis Risk?
OFATUMUMAB vs OFLOXACIN
OFATUMUMAB vs OLANZAPINE
OFATUMUMAB vs OLANZAPINE\SAMIDORPHAN L-MALATE
OFATUMUMAB vs OLAPARIB
OFATUMUMAB vs OLARATUMAB